GPP
VRTX icon

Great Point Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Great Point Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-85,000
Closed -$22.2M – 43
2022
Q1 		$22.2M Hold
85,000
– – 5.36% 9
2021
Q4 		$18.7M Hold
85,000
– – 4.15% 6
2021
Q3 		$15.4M Buy
+85,000
New +$16.6M 3.59% 9

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Great Point Partners's VRTX Position: Q2 2022 in Review

Great Point Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 85,000 shares — an estimated $22.2M sold.

Great Point Partners first reported a position in VRTX in Q3 2021 and held it in 3 quarters. The position peaked at $22.2M in Q1 2022. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Great Point Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Great Point Partners sold 85,000 Vertex Pharmaceuticals shares in Q2 2022, an estimated $22.2M.
  • Great Point Partners first reported a position in Vertex Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Great Point Partners's Vertex Pharmaceuticals position peaked at $22.2M in Q1 2022.
  • 1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Great Point Partners's 13F filing for Q2 2022, filed 15 Aug 2022.